Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PulteGroup, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while PulteGroup, Inc. trades at $124.99 (market cap $23.76B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.83% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PHM | |
|---|---|---|
Market Cap | $39.89B | $23.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $142.56 |
52-Week Low | $278.09 | $108.00 |
Enterprise Value | $38.15B | $23.72B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PulteGroup (PHM) trades at $124.75, up 0.83% on the day, with a bearish technical signal despite recent price strength. The stock shows mixed earnings performance with Q3 2025 beating estimates but subsequent quarters missing, while maintaining solid profitability with a 12.14% net margin. Recent news highlights new community developments and sector attention, though technical indicators suggest caution with RSI at neutral levels and key resistance at $125.
The outlook for PHM is balanced; analyst consensus targets $150.60 (21% upside) with 45% buy ratings, but near-term risks include margin pressure and housing market volatility. Earnings growth remains the key catalyst for sustained upside, while macroeconomic factors pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
